Extrawell Pharmaceutical Holdings Ltd ($858) - buy or sell? Stock discussion, ideas, forum

Extrawell Pharmaceutical Holdings Ltd

Extrawell Pharmaceutical Holdings Limited, through its subsidiaries, markets and distributes imported pharmaceutical products, healthcare, and nutritional products.

Industry: Pharmaceuticals

Ticker	Exchange	ISIN	Name
$858	HKEx Main Board	BMG3285Q1134	Code: 858

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 858 stock

Share your investment idea or question on Extrawell Pharmaceutical Holdings Ltd stock:

Latest twits on Extrawell Pharmaceutical Holdings Ltd (858)

No twits yet. Be the first to post!

Have a question about 858? Ask and other investors will be eager to help you.

Have an idea about 858? Share it with other investors.

Extrawell Pharmaceutical Holdings Ltd news

29/06/2016 Extrawell Pharmaceutical Holdings Ltd reports 94.2% Net Income decline in 2016 while 10.4% Revenue growth

29/06/2015 Extrawell Pharmaceutical Holdings Ltd reports 3,993% Net Income growth while 89.7 pp EBITDA Margin decline from 27.3% to -62.4%

Extrawell Pharmaceutical Holdings Ltd stock price chart

Extrawell Pharmaceutical Holdings Ltd financials

mln. HKD	FY2010	FY2011	FY2012

Revenue	196.3	198.8	157.4
EBITDA	18.369	7.896	17.564
Net income	14.624	11.567	20.414
CAPEX	1.423	11.249	2.743
Debt	0.000	0.000	0.000
Cash	105.0	124.6	140.1

Extrawell Pharmaceutical Holdings Ltd news

About Extrawell Pharmaceutical Holdings Ltd

Extrawell Pharmaceutical Holdings Limited, through its subsidiaries, markets and distributes imported pharmaceutical products, healthcare, and nutritional products. The Company also develops, manufactures, and sells pharmaceutical products in China. In addition, Extrawell exploits gene inventions, researches genome technology, and develops and manufactures genechips.